Kinji Fuchikami
Director/Board Member at NapaJen Pharma, Inc.
Profile
Mr. Kinji Fuchikami is Venture Partner at MVC Corp.
He comes with over 10 years of experience in drug discovery researches from gene discovery to preclinical research.
Prior to joining MVC, he worked for 12 years at Research Center Kyoto, in Bayer Yakuhin, Ltd.
At Bayer, his primary focus was kinase inhibitors, respiratory diseases, inflammatory diseases and allergy.
Mr. Fuchikami holds an M.Sc.
In the field of Medical Sciences from Osaka University Medical School.
Kinji Fuchikami active positions
| Companies | Position | Start |
|---|---|---|
Mitsui & Co. Global Investment Ltd.
 Mitsui & Co. Global Investment Ltd. Investment ManagersFinance Mitsui & Co. Global Investment Ltd is a private Equity/venture Capital firm, a subsidiary of Mitsui & Co., Ltd. founded in 1996. The firm is headquartered in Tokyo. | Private Equity Investor | 2004-11-30 |
NapaJen Pharma, Inc.
 NapaJen Pharma, Inc. Pharmaceuticals: MajorHealth Technology NapaJen Pharma, Inc. develops drug delivery technology solutions through cellular transport pathways. Its products include lead platform and drug delivery. The firm specializes in the development of novel drug delivery systems by utilizing natural transport pathways whose cells are used to move molecular cargo into themselves and across internal compartments. The company was founded by Dr. Kazuo Sakurai and Hironori Ando in December 2004 and is headquartered in Burlingame, CA. | Director/Board Member | 2011-04-21 |
Former positions of Kinji Fuchikami
| Companies | Position | End |
|---|---|---|
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Director/Board Member | - |
Training of Kinji Fuchikami
| Osaka University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Mitsui & Co. Global Investment Ltd.
Mitsui & Co. Global Investment Ltd. Investment ManagersFinance Mitsui & Co. Global Investment Ltd is a private Equity/venture Capital firm, a subsidiary of Mitsui & Co., Ltd. founded in 1996. The firm is headquartered in Tokyo. | Finance |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Health Technology |
NapaJen Pharma, Inc.
NapaJen Pharma, Inc. Pharmaceuticals: MajorHealth Technology NapaJen Pharma, Inc. develops drug delivery technology solutions through cellular transport pathways. Its products include lead platform and drug delivery. The firm specializes in the development of novel drug delivery systems by utilizing natural transport pathways whose cells are used to move molecular cargo into themselves and across internal compartments. The company was founded by Dr. Kazuo Sakurai and Hironori Ando in December 2004 and is headquartered in Burlingame, CA. | Health Technology |
- Stock Market
- Insiders
- Kinji Fuchikami
